Table 1 Clinical characteristics at initiation of 7 bDMARDs (bDMARDs-naïve cases)
Variable | ABT (n = 390) | ADA (n = 374) | CZP (n = 135) | ETN (n = 616) | GLM (n = 208) | IFX (n = 650) | TCZ (n = 364) |
|---|---|---|---|---|---|---|---|
Age (years) | 65.5 ± 12.4 | 55.3 ± 12.8 | 58.1 ± 16.8 | 55.5 ± 15.9 | 62.0 ± 14.8 | 52.9 ± 13.4 | 56.6 ± 14.4 |
Female sex (%) | 81.2 | 79.4 | 88.8 | 86.7 | 86.1 | 78.0 | 78.2 |
Disease duration (years) | 9.2 ± 12.4 | 5.0 ± 7.5 | 4.7 ± 7.6 | 8.3 ± 8.7 | 7.3 ± 10.0 | 6.9 ± 8.4 | 7.4 ± 9.4 |
RF positivity (%) | 86.6 | 73.8 | 86.2 | 83.1 | 75.6 | 74.2 | 74.0 |
ACPA positivity (%) | 84.3 | 75.9 | 85.7 | 83.2 | 73.2 | 82.9 | 82.1 |
DAS28-ESR | 4.4 ± 1.2 | 4.1 ± 1.2 | 4.6 ± 1.4 | 4.4 ± 1.4 | 4.3 ± 1.2 | 4.5 ± 1.6 | 4.6 ± 1.5 |
CDAI | 17.7 ± 9.6 | 14.7 ± 9.1 | 22.2 ± 12.9 | 17.3 ± 8.8 | 17.2 ± 11.5 | 18.5 ± 12.4 | 18.1 ± 9.8 |
HAQ-DI | 1.2 ± 0.8 | 0.7 ± 0.6 | 1.2 ± 0.8 | 0.9 ± 0.8 | 1.1 ± 0.8 | 1.1 ± 0.9 | 1.1 ± 0.8 |
PSL usage (%) | 44.2 | 32.8 | 44.8 | 39.2 | 38.9 | 36.4 | 45.7 |
PSL dose (mg/day) | 3.1 ± 7.3 | 2.9 ± 4.9 | 1.7 ± 2.6 | 2.8 ± 3.6 | 2.3 ± 3.6 | 3.1 ± 5.9 | 2.8 ± 3.9 |
MTX usage (%) | 49.1 | 72.0 | 76.1 | 39.4 | 76.0 | 100.0 | 51.2 |
MTX dose (mg/week) | 8.1 ± 2.8 | 9.4 ± 3.1 | 9.4 ± 2.9 | 8.0 ± 2.8 | 9.2 ± 2.9 | 8.2 ± 2.5 | 8.8 ± 3.0 |
Starting date 2001–2009 (%) | 0.0 | 13.6 | 0.0 | 40.4 | 1.0 | 60.9 | 11.5 |
Starting date 2010–2013 (%) | 35.9 | 53.7 | 12.6 | 42.0 | 40.4 | 30.2 | 47.3 |
Starting date 2014–2019 (%) | 64.1 | 32.7 | 87.4 | 17.6 | 58.7 | 8.9 | 41.2 |